Home
Clinical Trials
Intravenous VAL-1221 Lafora E...

Intravenous VAL-1221 Lafora Expanded Access Protocol

Last Updated: 2023-07-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

AVAILABLE

Study Classification

EXPANDED_ACCESS

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Only qualified physicians treating a Lafora Disease patient may request VAL-1221 Expanded Access treatment under the Parasail Lafora Expanded Access Protocol (LEAP). According to FDA guidance, this protocol can enroll up to 10 patients. However, individual patient inclusion will ultimately be dependent on protocol eligibility, site geography, treatment requirements, and available supply of the investigational therapy. Inquiring physicians can submit a request by contacting the Central Contact personnel listed below in Contacts/Locations.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

An Expanded Access Protocol for Sebelipase Alfa for Patients With Lysosomal Acid Lipase Deficiency

NCT02376751

Lysosomal Acid Lipase Deficiency

NO_LONGER_AVAILABLE

Investigational Study of Oral Fish Oil in Treating Parenteral Nutrition Associated Liver Disease

NCT01191177

Liver Disease Short Bowel Syndrome

WITHDRAWN PHASE1/PHASE2

Compassionate Use of Omegaven in the Treatment of Parenteral Nutrition Induced Hepatic Injury

NCT02010034

Liver Disease Impaired Liver Function Parenteral Nutrition Associated Liver Disease

COMPLETED NA

Expanded Access of Omegaven IV Fat Emulsion to Infants and Children With PNALD

NCT02929303

Total Parenteral Nutrition-induced Cholestasis

APPROVED_FOR_MARKETING

Safety, Tolerability and Fat Absorption Using Enteral Feeding In-line Enzyme Cartridge (Relizorb)

NCT02598128

Exocrine Pancreatic Insufficiency

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lafora Disease

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

VAL-1221

VAL-1221 20mg/kg intravenous (IV) infusion every other week

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Documented genetic diagnosis of Lafora Disease (LD) based on likely pathogenic or pathogenic variants in both alleles of either the EPM2A or the EPM2B gene
* Mid-stage in evolution of LD between 12 and 28 years of age
* Able and willing to comply with the protocol, including travel to Protocol Center, procedures, measurements and visits, including:

* Adequately supportive psychosocial circumstances, in the opinion of the Investigator
* Caregiver/trial partner committed to facilitate patient's involvement in the study who is reliable, competent, at least 18 years of age

Exclusion Criteria

* Have any other conditions, which, in the opinion of the Investigator or Sponsor would make the participant unsafe for inclusion or could interfere with the participant participating in or completing the protocol

Minimum Eligible Age

12 Years

Maximum Eligible Age

28 Years

Eligible Sex

ALL

Accepts Healthy Volunteers